Overview
Tesamorelin is a GHRH analog distinguished by its full 44-amino-acid sequence, which preserves the complete receptor contact surface of the native hormone, plus an N-terminal trans-3-hexenoic acid modification that blocks DPP-IV cleavage and extends its active window without changing receptor binding. Research interest centers on the GH/IGF-1 axis and the metabolic consequences of sustained GHRHR activation — particularly in visceral adipose tissue biology.
Mechanism of Action
Tesamorelin engages GHRHR on pituitary somatotroph preparations, activating Gs-coupled adenylyl cyclase and cAMP accumulation, with downstream PKA activity driving GH granule exocytosis and somatotroph transcription. Elevated GH output stimulates hepatic IGF-1 production through JAK2/STAT5 signaling, engaging downstream PI3K/Akt and MAPK/ERK cascades in target tissues. In visceral adipose preparations, GH axis activation has been associated with hormone-sensitive lipase stimulation and lipolytic signaling — an adipose-selective profile studied in metabolic models.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder
- CAS Number: 901758-09-6
- Molecular Weight: ~5196 g/mol
- Chemical Formula: C₂₂₃H₃₇₀N₇₂O₆₉S
- Synonyms: TH9507, Trans-3-hexenoic acid-GHRH(1-44)
Research Applications
- GHRHR binding and receptor pharmacology
- GH axis and somatotroph signaling studies
- IGF-1 pathway and JAK2/STAT5 research
- Visceral adipose lipolysis modeling
- DPP-IV resistance and peptide stability research





